Porton(300363.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Porton
300363.SZ
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial in China and internationally. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. It also offers crystallization, bio catalysis, metal catalysis, flow chemistry, prep-chromatography, and milling.
2.805 T
300363.SZMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking33/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.43%C
    • Profit Margin3.67%C
    • Gross Margin30.60%C
  • Growth ScoreB
    • Revenue YoY11.78%B
    • Net Profit YoY165.17%A
    • Total Assets YoY-2.03%D
    • Net Assets YoY1.45%C
  • Cash ScoreB
    • Cash Flow Margin524.39%A
    • OCF YoY11.78%B
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreB
    • Gearing Ratio35.31%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Porton released its performance for the first three quarters, with a net profit attributable to the parent company of 79.9154 million yuan, an increase of 138.71%

    Zhitong·
    SZ
    300363
    +5.25%
    Zhitong·
    SZ
    300363
    +5.25%

    Porton issued a profit warning, expecting a net profit attributable to shareholders of 73.2 million to 88.2 million yuan in the first three quarters, turning losses into profits

    Zhitong·
    SZ
    300363
    +5.25%
    Zhitong·
    SZ
    300363
    +5.25%

    Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

    Zhitong·
    SH
    603127
    +0.34%
    HK
    06127
    +2.16%
    SZ
    002262
    -1.16%
    Zhitong·
    SH
    603127
    +0.34%
    HK
    06127
    +2.16%
    SZ
    002262
    -1.16%

    Zhejiang Merchants Securities: The growth trend of the CXO sector in 25H1 continues to improve, and the construction projects remain at a high level

    Zhitong·
    SZ
    300347
    -0.75%
    HK
    03347
    -1.61%
    SZ
    300725
    -1.63%
    Zhitong·
    SZ
    300347
    -0.75%
    HK
    03347
    -1.61%
    SZ
    300725
    -1.63%

    Porton Biotech and Tianyu Life have reached a strategic cooperation to jointly promote the research and commercialization of NK cell therapy

    Zhitong·
    SZ
    300363
    +5.25%
    Zhitong·
    SZ
    300363
    +5.25%
    © 2026 Longbridge｜Disclaimer